End-of-day quote
Other stock markets
|
||
- | - |
05-07 | AstraZeneca target raised; Antofagasta lowered | AN |
05-01 | HSS Hire annual profit falls amid investment spending; CFO to depart | AN |
Sales 2024 * | 347M 438M 0 597M | Sales 2025 * | 360M 453M 0 618M | Capitalization | 69.09M 87.02M 0 119M |
---|---|---|---|---|---|
Net income 2024 * | 6M 7.56M - 10.31M | Net income 2025 * | 7M 8.82M - 12.03M | EV / Sales 2024 * | 0.47 x |
Net Debt 2024 * | 95.22M 120M 0 164M | Net Debt 2025 * | 99.75M 126M 0 171M | EV / Sales 2025 * | 0.47 x |
P/E ratio 2024 * |
11.1
x | P/E ratio 2025 * |
9.81
x | Employees | - |
Yield 2024 * |
5.89% | Yield 2025 * |
6.06% | Free-Float | 24.68% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Ashmore
CEO | Chief Executive Officer | 60 | 17-05-31 |
Paul Quested
DFI | Director of Finance/CFO | 54 | 16-04-30 |
Daniel Joll
BRD | Director/Board Member | - | 15-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 15-01-08 | |
Director/Board Member | 71 | 15-01-08 | |
Alan Peterson
CHM | Chairman | 77 | 12-11-30 |
1st Jan change | Capi. | |
---|---|---|
+21.11% | 46.39B | |
+9.15% | 32.45B | |
+22.11% | 17.39B | |
-11.01% | 7.47B | |
+17.79% | 5.44B | |
+4.96% | 4.49B | |
-2.25% | 3.71B | |
-8.82% | 2.65B | |
+20.09% | 2.22B |